The selective inhibition of vascular permeability factor (VPF) expression in ovarian carcinoma cell lines by a gonadotropin-releasing hormone (GnRH) agonist

T. A. Olson, D. Mohanraj, S. Ramakrishnan

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

GnRH agonists have been found to be clinically useful in several hormone-sensitive conditions, including cancer. However, there is controversy regarding a direct action of these agents on the pathologic tissue of a given disease process, in particular, tumors. In this study, we examined the effects of D-Trp6 -LHRH, a potent GnRH agonist, on the expression of an increasingly important angiogenesis factor, VPF (vascular permeability factor)l VEGF (vascular endothelial growth factor). Ovarian carcinoma cell lines exposed to D-Trp6 -LHRH in culture demonstrated a reversible inhibition of VPF mRNA expression and a parallel decrease in the endothelium-specific mitogenic activity of the conditioned media from these treated cultures. This study reports a novel activity of a GnRH agonist and provides a starting point to investigate the in vivo anti-angiogenic properties of GnRH peptide analogs.

Original languageEnglish (US)
Pages (from-to)905-910
Number of pages6
JournalInternational Journal of Oncology
Volume6
Issue number4
StatePublished - Jan 1 1995

Keywords

  • Gonadotropin-releasing hormone (GnRH)
  • Ovarian cancer
  • Vascular endothelial growth factor (VEGF)
  • Vascular permeability factor (VPF)

Fingerprint

Dive into the research topics of 'The selective inhibition of vascular permeability factor (VPF) expression in ovarian carcinoma cell lines by a gonadotropin-releasing hormone (GnRH) agonist'. Together they form a unique fingerprint.

Cite this